CY1123838T1 - Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματος - Google Patents
Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματοςInfo
- Publication number
- CY1123838T1 CY1123838T1 CY20211100136T CY211100136T CY1123838T1 CY 1123838 T1 CY1123838 T1 CY 1123838T1 CY 20211100136 T CY20211100136 T CY 20211100136T CY 211100136 T CY211100136 T CY 211100136T CY 1123838 T1 CY1123838 T1 CY 1123838T1
- Authority
- CY
- Cyprus
- Prior art keywords
- conjugate vaccine
- polystenes
- pneumococcal
- pneumococcal conjugate
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία σύνθεση πολυσθενούς εμβολίου Πνευμονιοκοκκικού συζεύγματος (PCV) που περιλαμβάνει: 1) τουλάχιστον 12 καψικούς πολυσακχαρίτες που επιλέγονται από ορότυπους 1, 3, 4, 5, 6Β, 7F, 9Ν, 9V, 15Β, 14, 18C, 19Α, 19F, 22F, 23F και 33F του S. pneumoniae ενεργοποιημένοι με CDAP και συζευγμένοι σε πρωτεΐνη φορέα που επιλέγεται από CRM197, πνευμονιοκοκκική πρωτεΐνη Α επιφανείας (PspA), πνευμονιοκοκκική πρωτεΐνη προσκολλητίνης (PsaA) ή συνδυασμό αυτών και 2) έναν φαρμακευτικά αποδεκτό φορέα, όπου η σύνθεση δεν περιέχει καψικό πολυσακχαρίτη από ορότυπο 6Α.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3140CH2015 | 2015-06-23 | ||
PCT/IN2016/000157 WO2016207905A2 (en) | 2015-06-23 | 2016-06-21 | Multivalent pneumococcal conjugate vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123838T1 true CY1123838T1 (el) | 2022-05-27 |
Family
ID=56738144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100136T CY1123838T1 (el) | 2015-06-23 | 2021-02-18 | Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματος |
Country Status (22)
Country | Link |
---|---|
US (1) | US11147863B2 (el) |
EP (1) | EP3313436B1 (el) |
JP (1) | JP6808658B2 (el) |
CN (1) | CN107810010A (el) |
AU (1) | AU2016285017B2 (el) |
BR (1) | BR112017028130A2 (el) |
CA (1) | CA2989230A1 (el) |
CY (1) | CY1123838T1 (el) |
DK (1) | DK3313436T3 (el) |
EA (1) | EA037373B1 (el) |
ES (1) | ES2857474T3 (el) |
HR (1) | HRP20210373T1 (el) |
HU (1) | HUE053272T2 (el) |
LT (1) | LT3313436T (el) |
MX (1) | MX2017016828A (el) |
PL (1) | PL3313436T3 (el) |
PT (1) | PT3313436T (el) |
RS (1) | RS61440B1 (el) |
SA (1) | SA517390539B1 (el) |
SI (1) | SI3313436T1 (el) |
WO (1) | WO2016207905A2 (el) |
ZA (1) | ZA201708713B (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
PE20240927A1 (es) * | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
US11058757B2 (en) | 2016-03-31 | 2021-07-13 | Pogona, LLC | Saccharide-polypeptide conjugate compositions and methods of use thereof |
UA126385C2 (uk) * | 2016-09-30 | 2022-09-28 | Байолоджикал І Лімітед | Композиції полівалентної пневмококової вакцини, що містять кон'югати полісахарид-білок |
CA3048981A1 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
KR102634811B1 (ko) * | 2017-06-10 | 2024-02-06 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
CN108003240B (zh) * | 2017-12-04 | 2020-06-05 | 西安德轩驰生物科技有限公司 | 一种海水养殖鱼多联抗独特型卵黄抗体疫苗及其制备方法 |
JP7369123B2 (ja) | 2017-12-06 | 2023-10-25 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖類-タンパク質コンジュゲートを含む組成物およびその使用方法 |
US11123417B2 (en) | 2018-02-05 | 2021-09-21 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
AU2019256218A1 (en) | 2018-04-18 | 2020-12-03 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
EA202191638A1 (ru) * | 2018-10-12 | 2021-12-27 | Байолоджикал И Лимитед | Мультивалентная вакцина на основе конъюгата пневмококковый полисахарид-белок |
MA54533A (fr) | 2018-12-19 | 2022-03-30 | Merck Sharp & Dohme | Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation |
EP3900739A1 (en) * | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
ES2204900T3 (es) | 1992-02-11 | 2004-05-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Estructura inmuinogena de doble vector. |
ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
CA2215933C (en) | 1995-03-22 | 2009-10-13 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN102716480B (zh) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN101378778B (zh) * | 2005-12-22 | 2013-02-06 | 葛兰素史密丝克莱恩生物有限公司 | 肺炎球菌多糖缀合物疫苗 |
KR101838938B1 (ko) | 2006-03-17 | 2018-03-15 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 복합 다가 면역원성 콘쥬게이트의 제조 방법 |
AU2008267208B2 (en) | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
CN101590224A (zh) * | 2009-06-30 | 2009-12-02 | 广州精达医学科技有限公司 | 高效14价肺炎球菌结合疫苗 |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CN103623401A (zh) | 2012-08-23 | 2014-03-12 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
CN103656632B (zh) | 2012-09-24 | 2016-01-13 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖组合物、其制备方法及应用 |
CN103656631B (zh) | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法 |
KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CN104069488A (zh) | 2013-03-29 | 2014-10-01 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
WO2016079755A1 (en) | 2014-11-20 | 2016-05-26 | Biological E Limited | Codon optimized polynucleotide for high level expression of crm197 |
-
2016
- 2016-06-21 CN CN201680037079.2A patent/CN107810010A/zh active Pending
- 2016-06-21 DK DK16753710.9T patent/DK3313436T3/da active
- 2016-06-21 BR BR112017028130A patent/BR112017028130A2/pt active Search and Examination
- 2016-06-21 HU HUE16753710A patent/HUE053272T2/hu unknown
- 2016-06-21 PL PL16753710T patent/PL3313436T3/pl unknown
- 2016-06-21 US US15/772,771 patent/US11147863B2/en active Active
- 2016-06-21 SI SI201631120T patent/SI3313436T1/sl unknown
- 2016-06-21 EA EA201890431A patent/EA037373B1/ru unknown
- 2016-06-21 AU AU2016285017A patent/AU2016285017B2/en active Active
- 2016-06-21 WO PCT/IN2016/000157 patent/WO2016207905A2/en active Application Filing
- 2016-06-21 PT PT167537109T patent/PT3313436T/pt unknown
- 2016-06-21 JP JP2017566871A patent/JP6808658B2/ja active Active
- 2016-06-21 CA CA2989230A patent/CA2989230A1/en active Pending
- 2016-06-21 ES ES16753710T patent/ES2857474T3/es active Active
- 2016-06-21 RS RS20210164A patent/RS61440B1/sr unknown
- 2016-06-21 EP EP16753710.9A patent/EP3313436B1/en active Active
- 2016-06-21 MX MX2017016828A patent/MX2017016828A/es unknown
- 2016-06-21 LT LTEP16753710.9T patent/LT3313436T/lt unknown
-
2017
- 2017-12-13 SA SA517390539A patent/SA517390539B1/ar unknown
- 2017-12-20 ZA ZA2017/08713A patent/ZA201708713B/en unknown
-
2021
- 2021-02-18 CY CY20211100136T patent/CY1123838T1/el unknown
- 2021-03-03 HR HRP20210373TT patent/HRP20210373T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HUE053272T2 (hu) | 2021-06-28 |
US11147863B2 (en) | 2021-10-19 |
EP3313436A2 (en) | 2018-05-02 |
HRP20210373T1 (hr) | 2021-04-30 |
WO2016207905A3 (en) | 2017-02-09 |
BR112017028130A2 (pt) | 2018-08-28 |
CA2989230A1 (en) | 2016-12-29 |
RS61440B1 (sr) | 2021-03-31 |
JP6808658B2 (ja) | 2021-01-06 |
DK3313436T3 (da) | 2021-03-08 |
SI3313436T1 (sl) | 2021-09-30 |
US20190240308A1 (en) | 2019-08-08 |
ZA201708713B (en) | 2019-08-28 |
ES2857474T3 (es) | 2021-09-29 |
AU2016285017B2 (en) | 2022-03-03 |
EA037373B1 (ru) | 2021-03-22 |
JP2018518512A (ja) | 2018-07-12 |
WO2016207905A2 (en) | 2016-12-29 |
SA517390539B1 (ar) | 2021-05-24 |
EP3313436B1 (en) | 2020-12-23 |
AU2016285017A1 (en) | 2018-01-04 |
PL3313436T3 (pl) | 2021-06-14 |
EA201890431A1 (ru) | 2018-06-29 |
LT3313436T (lt) | 2021-06-10 |
CN107810010A (zh) | 2018-03-16 |
MX2017016828A (es) | 2018-09-18 |
PT3313436T (pt) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123838T1 (el) | Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματος | |
MX2022014850A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
MX2022009928A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
MX2022009927A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
BR112020004509A8 (pt) | Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado | |
BR112019001971A2 (pt) | composição conjugada de polissacarídeo-proteína pneumocócica multivalente | |
PE20161095A1 (es) | Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos | |
TN2012000377A1 (en) | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition | |
BR112019001995A2 (pt) | composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína | |
PH12015501269B1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
MX2016009468A (es) | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. | |
EP3980055A4 (en) | IMMUNOGENIC PNEUMOCOCCUS POLYSACCHARID-PROTEIN CONJUGATE OF SEROTYPE 35B AND CONJUGATION METHODS FOR ITS PRODUCTION | |
MX2021014948A (es) | Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. | |
JOP20190038B1 (ar) | تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته | |
IL284349A (en) | A polyvalent polysaccharide-protein conjugate vaccine of the show dot | |
AR109377A1 (es) | Composición conjugada neumocócica multivalente de polisacárido y proteína | |
IN2014MU00349A (el) | ||
AR093161A1 (es) | Composicion de conjugados polisacarido-proteina neumococicos multivalente |